Source: ExploreBit

ValenzaBio: ACELYRIN acquires ValenzaBio

ACELYRIN late stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology today announces acquisition ValenzaBio

Read full article »
ValenzaBio's Competitors | ValenzaBio's News | ValenzaBio's Financials
Stay up-to-date with the latest news on ValenzaBio
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Patrick J. Crutcher's photo - Chairman & CEO of ValenzaBio

Chairman & CEO

Patrick J. Crutcher

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on ValenzaBio